• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    A strategy for population pharmaceutical quality assessment based on quality by design

    2021-11-11 13:37:48YuZhoChngqinHuShngchenYoLihuiYinXiomeiLing
    Journal of Pharmaceutical Analysis 2021年5期

    Yu Zho , Chngqin Hu , Shngchen Yo , Lihui Yin , Xiomei Ling

    a NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, National Institutes for Food and Drug Control, Beijing,102629, China

    b Acedemy for Advanced Interdisciplinary Studies, Peking University, Beijing,100088, China

    c Peking University Health Science Center, Peking University, Beijing,100191, China

    Keywords:Population pharmaceutical quality Quality by design (QbD)Crucial evaluation attributes (CEAs)Process indicators (PIs)Improved statistical process control (SPC)Risk assessment

    ABSTRACT From a regulatory perspective, drug quality consistency evaluation must concern different processes used for the same drug. In this study, an assessment strategy based on quality by design (QbD) was developed for population pharmaceutical quality evaluation. A descriptive analysis method based on QbD concept was first established to characterize the process by critical evaluation attributes (CEAs).Then quantitative analysis method based on an improved statistical process control (SPC) method was established to investigate the process indicators (PIs) in the process population, such as mean distribution, batch-to-batch difference and abnormal quality probability. After that rules for risk assessment were established based on the SPC limitations and parameters.Both the SPC parameters of the CEAs and the risk of PIs were visualized according to the interaction test results to obtain a better understanding of the population pharmaceutical quality. Finally, an assessment strategy was built and applied to generic drug consistency assessment, process risk assessment and quality trend tracking. The strategy demonstrated in this study could help reveal quality consistency from the perspective of process control and process risk, and further show the recent development status of domestic pharmaceutical production processes. In addition, a process risk assessment and population quality trend tracking provide databased information for approval. Not only can this information serve as a further basis for decisionmaking by the regulatory authority regarding early warnings, but it can also reduce some avoidable adverse reactions. With continuous addition of data, dynamic population pharmaceutical quality is meaningful for emergencies and decision-making regarding drug regulation.

    1. Introduction

    Due to the cost and time investment necessary for new drug research and development, a large gap is always present between the demand for brand-name drugs and the purchasing power of patients, which gives generic drugs an enormous an market potential [1]. Furthermore, the economic benefits of generic drugs,such as reducing national medical expenditures, have attracted government attention.Therefore,countries and regions worldwide,including the US,the European Union(EU)and Japan,are generally promoting the use of generic drugs[2].China is a large generic drug market that primarily relies on domestic generic pharmaceutical products. In addition, the volume and potential of generic drug exports should not be underestimated [3]. Undoubtedly, the rapid development of generic drugs has created new challenges for regulation,particularly for the drug review and evaluation system.

    Since China joined the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use(ICH) in June 2017, the pharmaceutical industry in China has been required to conform with international standards. Thus, both the drug regulatory authorities and research and development institutions in the pharmaceutical industry must gradually transform their processes and implement the highest international technical standards and guidelines.Since 2016,the Chinese government has issued a series of regulations and drafts concerning generic drug consistency evaluation that aim to effectively enhance the innovation capability and international competitiveness of the domestic pharmaceutical industry [4].

    In the past 10 years, the Chinese government has invested millions of RMB each year in sampling and evaluating listed drugs according to the current quality standards; this effort is known as the National Evaluation Sampling and Test Project (NESTP). The purpose of NESTP is to evaluate the quality status of domestic medicines,analyze the main product quality problems,identify the relevant process problems and improve the current quality standard, such as monographs in the Chinese Pharmacopeia (ChP).NESTP can be said to be the most comprehensive and timely drug quality information source currently available in China. According to its annual report,although the pass rate for chemical drugs was high (above 98%), many types of problems were found during the project studies, particularly in production processes and process control. This indicates that the gaps between domestic generic drugs and drugs imported from the EU and the US stem from the process control level, which is reflected in differences between batches and sometimes even within a batch[5]. Therefore, a focus on process when assessing quality consistency is necessary and crucial.

    Both the EU and the US have implemented process analytical technology (PAT)-based process validation and real-time release(RTR) testing in continuous manufacturing process, which allow production of better-quality final products[6,7].However,in China,batch mode is the mainstream, and PAT is not widely used in the pharmaceutical industry, and currently there is no RTR testing protocol that is supported by policy.From a regulatory perspective,quality consistency evaluation must characterize different processes for the same product. How should we assess products that are produced both with and without PAT? Fortunately, since the current Good Manufacturing Practice (cGMP) standards were launched,the current quality standards are based on the quality by design(QbD)concept instead of quality by test(QbT).QbD requires manufacturers to fully understand their own processes and ensure continuous improvement in the quality of final products [8,9].There is a wealth of information related to the processes in the readily measurable attributes (e.g., assay, impurities and dissolution) of final products. From the regulation point of view, the evolution is a process of seeking common ground while reserving differences, where the quality attributes are the common ground and process parameters are the differences. Thus, we need to find universal indicators and methods to characterize different processes used for the same product.

    Recently, the U.S. Food and Drug Administration (USFDA) proposed the knowledge-aided assessment and structured application(KASA) system to improve the consistency and objectivity of regulatory assessments [10]. Statistical methods, such as six sigma theory and statistical process control (SPC), have been more and more applied to process monitoring in the pharmaceutical industry[11,12].In addition to process monitoring,statistics are also widely applied in annual review of drug quality. T^orres et al. [13] used multivariate statistical process control (MSPC) method to analyze the historical quality data of hydrochlorothiazide tablets in 2009 and 2013,and evaluated the process correction in the past 11 years.Kharbach et al. [14] used six process indicators from the annual product review data to perform principal component analysis(PCA)based MSPC analysis, found the interaction of process indicators,and detected abnormal products by Hotelling T2. Different from process monitoring and annual review, population quality evaluation is to find out the distribution of process levels. Although PCA based MSPC can well characterize the population process level,the evaluation is not directional,poor in interpretability,and cannot be traced back to individual process indictors [15].

    Furthermore,unlike the original drugs pharmaceutical research and manufacturing[16],generic drug evaluation has the advantage that most safety and efficiency information is known. When evaluating the generic drug,attention should also be paid to the quality controllability related to process amplification as well as safety and efficiency. This kind of indirect evaluation could facilitate obtainment of certain forward-looking trends based on retrospective data, which make up for the lack of direct evaluation of clinical practice such as expensive,hindsight and individualized difference.Our study was created to fill the gap.

    In this study,an assessment strategy focusing on evaluating the quality controllability based on population pharmaceutical quality data was established to explore commonality of generic drugs process evaluation. Critical evaluation attribute (CEA) was defined and an improved SPC method for population quality based on CEAs was developed to determine the limitations and parameters closely related to the process performance. Ceftriaxone sodium for injection and aztreonam for injection were taken as examples to demonstrate the strategy application for quality consistency evaluation.

    2. Materials and methods

    2.1. Data and programs

    All data and information were collected from NESTP and relavent literature. The data on ceftriaxone sodium for injection included 551 batches from 48 manufacturers for process assessment,and the data on aztreonam for injection included 233 batches from 27 manufacturers; all the data were collected over two nonconsecutive years for an annual review assessment of process consistency.

    The programs for computation were developed using the MATLAB platform (Version 2018a).

    2.2. Descriptive analysis method

    In our study, the objects were population pharmaceutical quality of a certain drug instead of individual quality of a certain product. The drug quality standard was the regulation of various inspection items, indicators, limits and ranges, etc. to ensure the quality of drugs, which comprehensively reflect the purity, impurities, hydrogen, sterility and even physicochemical properties of the drug. In traditional pharmaceutical analysis and evaluation system, all the items are evaluated with the fixed limitation in quality standard one by one, where the variation and links are always neglected.It is precisely these variation and links that reflect the quality of the production processes. Therefore, to describe a population quality, the main point is to describe the quality of production process.

    From a QbD regulation perspective, although the production processes are complex and diverse,our concept is to describe final products of different process parameters by common quality elements-quality target, quality variation and risks (Fig.1), where the variation is controllable, and risk is uncontrollable. For a population of production processes used for the same product, the mean distribution,batch-to-batch difference and abnormal quality probability well represented the elements of QbD and were defined as process indicators (PIs) in our study.

    2.3. Quantitative analysis method

    Fig.1.The quality of pharmaceutical processes from the QbD regulation perspective based on end product characteristics.

    SPC technology is the most efficient method for process analysis and control, which continues to be an important and indispensable tool for quality management, research and healthcare improvement [17]. The principle [18] is to preplan the sampling interval and sample capacity to obtain real-time process data under the premise that the sample population follows a normal distribution with an upper control limit(UCL),lower control limit(LCL),centerline(CL)and a sequence of sample statistic values.In industry,thecontrol chart and the R control chart are commonly used to detect abnormal points in the process, and they are also the most widely used methods in process monitoring and quality annual review. However, the population data collected from NESTP are retrospective data rather than real-time process data,and the sampling interval and sample capacity are random and uncontrollable. Furthermore, the range R in the R control chart,which reflects the degree of data dispersion,has the disadvantage of fatal dependence on the sample size,reliance on a tiny amount of information and susceptibility to individual outliers and thus cannot completely characterize batch-to-batch differences.Therefore, the classic SPC method commonly used in process monitoring and quality annual review is not applicable for the quantitative analysis of population quality and thus an improved SPC method was developed for the quantitative analysis of the population process distribution and the individual processes relative to the population distribution (mean distribution), the batch-to-batch difference distribution (difference distribution)and the abnormal product probability (abnormal probability).

    2.3.1. Mean distribution

    Generally, for a specific drug product, domestic production processes are at a similar level, and the process characteristics of the population, despite its variety, are in line with the normality assumption. If the number of NESTP samples (processes) is sufficiently representative,the population processes can be considered to follow a normal distribution with an unknown μ and σ. Due to the severe heterogeneity in sample size(the number of batches of each product), in the present study, the median of the process samples was used to characterize the individual process levels and estimate the μ and σ of the normal population process distribution.The average median of each process sample was used to estimate the μ of the population process, and the median deviation of each process was used to estimate the σ of the population process.

    Suppose there aremprocess samples with sample sizes ofni(i=1,2,…, m), and the median of each process sample can be calculated using Formula (1):

    Then, the mean value μ of the population process can be estimated using Formula (2):

    The population process standard deviation σ is estimated using the median of the average absolute deviation (MAAD) [19] according to Formula (3):

    and when tα/2 = 3, the 3σ level is defined as the good quality process control limit A0[LCL0,UCL0],and when tα/2=6,the 6σ level is defined as the population quality process control limit A1[LCL1,UCL1].The pharmacopeia control limit[LCLp,UCLp]is defined as U.If the attribute is one-sided, such as with impurity content, LCL0and LCL1should be forced to equal LCLp. In addition, the relationship between A1and U provides information on the suitability of the actual current quality standard to the current process control level.

    2.3.2. Difference distribution

    We used the semi-interquartile range (Rq), which is half of the difference between the third quartile and the first quartile or the 75th percentile and the 25th percentile (Formula (5)), to describe the batch-to-batch difference for each process sample.Here,we did not use the range (R=xmax- xmin) as the normal control chart becauseRqis not susceptible to interference by individual anomalous data and is superior in characterizing variation in the population process.

    The mean and standard deviation ofRqcan be calculated with Formulas (6) and (7):

    Then, the 100 (1-α) % confidence interval B ofcan be calculated using Formula (8):

    and when tα/2=3,the 3σ level is defined as the good quality interbatch difference B0[RqLCL0, RqUCL0], and when tα/2 = 6, the 6σ level is defined as the population batch-to-batch difference control limit B1[RqLCL1, RqUCL1].

    2.3.3. Abnormal probability

    The distribution of products within each process is expressed by the probability of being within the control limit of A1.We define the probability of exceeding A0as the abnormal quality probability,and it includes two cases:those that exceed A0but still fall below A1are around-corner products, whose probability is recorded as Pac(Formula (9)); those that are outside A1are substandard products,whose probability is recorded as Pss(Formula(10)).Obviously,the abnormal quality probability has a negative relationship with the quality of the process.

    The abnormal product probability of binary indicators is the percentage of the number of substandard products(ns)in the total number of samples (ni) of the process, recorded as Psi(Formula(11)).

    2.4. Interaction test

    An interaction test is developed to find representative of the chosen CEAs. The more orthogonal they are, the more representative of the population quality it is. Singular value decomposition(SVD) algorithm based PCA was applied to calculate orthonormal principal component coefficient of each quality attribute(QA).SVD has a less rounding error and effectively reduces the error of PCA information reconstruction.The principal component variances are the eigenvalues of the covariance matrix of CEAs. When variables are represented in the principal component space by a vector, the direction and length of the vector indicate the interaction of CEAs,which is a very important basis of visualization of both population parameters and risk distribution space.

    2.5. Risk assessment method

    Based on the SPC results,the process risk scoring was performed under the rules shown in Table 1. Grades 0, 0.5 and 1 were set to score the risk based on the distribution in the 3σ level,between the 3σ and 6σ level or outside the6σ level,respectively.Finally,the risk scores of each item were summed to obtain the risk assessment for each process.The smaller the risk score is,the better the process is.

    2.6. Assessment strategy

    The strategy for assessing population quality of pharmaceutical processes [20] is shown in Fig. 2. First of all, CEAs were selected.Generally, data from each manufacturer were considered valid when at least three batches were included. CEAs can be either the known critical quality attributes (CQAs) obtained from PAT or selected from attributes in the quality standard [21], such as identification, active pharmaceutical ingredient (API) content, impurities and specific formulation-related test items, according to experience. Secondly, CEAs were classified. CEAs might be measured on different scales, such as continuous or binary responses. Binary attributes, such as traits, identification, pyrogen and sterility, were added as additional attributes in the characterization only if positive attributes (FR≠0) appeared in the overall data. Of note, for the binary CEAs, the abnormal probability was calculated only when necessary. Thirdly, PIs were investigated by the descriptive and quantitative methods developed above. Then,data visualization can aid in obtaining a better understanding of both the process space and abnormal distribution and the synthesis process risk grade. When there were fewer than three CEAs representative PIs, a spatial vector was used for visualization in 2-or 3-dimensional space. When there were four or more chosen representative processes, either a dimension-reduction algorithm or a glyph plot was available.

    3. Results and discussion

    Two examples of an antibiotic injection were utilized to demonstrate the application of the strategy in two cases. As an example of a case in which a reference listed drug (RLD) was available, we performed a quality consistency assessment on generic ceftriaxone sodium injections, while to present a case in which an RLD was not available, we performed a process risk assessment and population quality trend tracking on generic aztreonam injections.

    3.1. Application of quality consistency assessment

    Ceftriaxone is a broad-spectrum cephalosporin launched by Roche under the brand name Rocephin in 1982 [22]. In China,dozens of manufacturers produce generic ceftriaxone.Rocephin,as well as the generic drugs, is a sterile powder injection containing ceftriaxone sodium (API). Therefore, Rocephin is the listed RLD. A clinical survey showed that the gaps between generic ceftriaxone and Rocephin are directly reflected in a slow clinical effect and the clarity of the solution [23,24]. The former is due to the low salt formation rate,and the latter is primarily related to the crystallinity[25]. Ceftriaxone sodium (Fig. 3) is a crystalline powder with a molecular formula that contains two sodium ions and 3.5 water molecules. The theoretical value of ceftriaxone and water in wet products should be 83.8%and 9.5%,respectively,and the theoretical ceftriaxone content in anhydrous ceftriaxone sodium can be calculated as 92.7%. Theoretically, an anhydrous ceftriaxone content of more than 92.7%indicates insufficient salt formation,while a water content less than 9.5% indicates insufficient crystallinity.Thus, the anhydrous ceftriaxone content and water content are closely related to the quality of ceftriaxone sodium for injection production process.

    In our study, we took these two attributes as the CEAs to perform the process assessment strategy. According to ChP, the anhydrous ceftriaxone content should not be less than 84.0%. We set an upper limit according to both theoretical value and the upper limit of European Pharmacopeia. Thus, the UAPIof the anhydrous ceftriaxone content [APILCLP,APIUCLP] is [84.0%, 94.6%]. While the water content should be in the range of 8.0%-11.0% according to ChP,and thus,the Uwaterof the water content[WaterLCLP,WaterUCLP]is [8.0%,11.0%]. Population parameters of domestic generic ceftriaxone sodium for injection were calculated using the quality data of 551 batches from 48 manufacturers,as shown in Table 2.The mean distribution of the water content was 8.75% (CLwater), with a 6σ level moving a little beyond theWaterLCLP,which indicates that thecrystallinity process needs to be improved. The mean distribution of the anhydrous ceftriaxone content was 91.25%, with a 6σ level moving far beyond theAPIUCLP, which indicates that there are universal problems in salt formation process of domestic products.Moreover, the batch-to-batch differences were appropriate and abnormal product probability (Pab) was around 10% of both CEAs.

    Table 1 Process risk scoring rules for CEAs.

    Fig.2.Flow chart showing the population quality assessment strategy.

    Fig. 4A shows a weak interaction of CEAs; therefore, both population parameter and risk distribution can be visualized in an orthogonal space(Fig.4B).As shown in Fig.4B,a 2D boxplot of the Rocephin process is also included in the space for comparison.The population parameter A0(green dash rectangle) covered the Rocephin process distribution(pink 2D boxplot),which proves that A0is consistent with RLD, although there is an obvious gap in process control levels compared with Rocephin. For some manufacturers such as M13,M26,M28,M35 and M42,the salt formation rates are seriously insufficient.Individual outliers appeared in M10,M11, M27 and M28, which indicates the risk of product failure.

    Fig.3.Molecular structure of ceftriaxone sodium.

    The process risk assessment was performed based on the PI values and risk scores, where the risk scores of the anhydrous ceftriaxone content captured the risk of salt formation and the risk scores of water content showed the risk of crystallinity (Table S1).As Fig. 5 shows, the ceftriaxone production process distribution space is divided into three risk grades: low-risk for a risk score below 1,mid-risk for a risk score between 1 and 2,and high-risk for a risk score greater than 2.And each process is described by vectors with coordinates of the assessment parameters. Most domestic processes are at risk grades 1 and 2,and those at risk grade 1 have a better process control level than those at risk grade 2. In addition,the risk assessment can also indicate the shortest plank requiring improvement for an individual process. For instance, the risk assessment of M24 is zero for the salt formation process but 1.0 for the crystallinity process, which indicates that this manufacturer should pay close attention to the crystallinity when raw materials are produced or purchased;the risk assessment of M26 is less than 0.5 for the crystallinity process but 2 for the salt formation process,suggesting that M26 should pay more attention to the latterprocess. Furthermore, for those close to the high-risk line, such as M28, the risk assessment calls attention to both processes.

    Table 2 Population parameters of domestic generic ceftriaxone sodium for injection.

    Fig.4.Interaction of CEAs and SPC graph of API and water content in generic ceftriaxone sodium injections.(A)The blue arrow lines are the CEA variable vectors and red points are the raw data distributing in the principal component space;(B)the red rectangle is U,the blue dashed rectangle is A1,the green dashed rectangle is A0,the pink 2D boxplot presents the data for Rocephin, the colored markers are the abnormal batches from different manufacturers, and those varied beyond U are marked.

    3.2. Process risk assessment and population quality trend tracking

    Aztreonam is a β-lactam antibiotic against gram-negative bacteria that was marketed by Squibb in 1986 under the brand name Azactam;it is a 25%(m/V)aqueous solution.Due to polymerization in water, the current formulation of aztreonam is a sterile powder injection containing aztreonam and arginine.Therefore,there is no RLD available for consistency evaluation. There are two types of production processes used for domestic generic aztreonam injection: a mixed powder process and a freeze-drying process. According to the NESTP report, although all the samples were qualified, the quality of the raw materials, the arginine feeding process control,and the freeze-drying and filling processes are the main factors affecting product quality. Thus, a production process assessment seems necessary and important.

    We used the anhydrous and arginine-free aztreonam content,average loading of the aztreonam content and total impurity content as CEAs to evaluate the process consistency. First, the anhydrous and arginine-free aztreonam content was calculated based on the aztreonam content, water content, and arginine content in the product,which could characterize the consistency of the mixed materials (MC). Second, the labeled amount of aztreonam content was calculated from the aztreonam content and the average loading, which reflects the stability of preparation production process(PS).Finally,according to previous research,impurities and degradants are the main quality factors that cause adverse reactions, and thus, the total impurity content was used to characterize the consistency of the API raw material(RC).

    According to ChP,both the API content and the impurities can be measured by HPLC, which stipulates that the anhydrous and arginine-free aztreonam content should be 91.0%-103.0%, the labeled amount content should be 90.0%-105%, and the impurity content should not be greater than 5%. Therefore, theMCU of anhydrous and arginine-free aztreonam content[MCLCLP,MCUCLP]is[91.0%,103%],thePSU of the labeled amount content[PSLCLP,PSUCLP]is[90.0%,105.0%]and theRCU of the total impurity content[RCLCLP,RCUCLP] is [0%, 5.0%].

    PIs were calculated from the processes of the 27 manufacturers of generic aztreonam for injection for the two years(Table 3).The mean distribution of anhydrous and arginine-free aztreonam content indicates that there were some issues with the MC process between 2012 and 2018 due to the formula change.The mean distribution of the labeled amount content indicates that although the PS process had been extensively improved by 2018,certain problems remained for future improvement.The mean distribution of the total impurity content indicates that the RC process had been improved from 2012 to 2018. The most recent PIs of batch-to-batch difference and abnormal probability showed the current status of a quality variation problem for the MC process and a high out-of-control risk for the PS process.

    Fig.5.Risk assessment for processes and the process vector distribution of generic ceftriaxone sodium injections. (The colored vectors distributed in the space represent each process of 48 manufacturers.)

    Table 3 2-year population parameters of domestic generic aztreonam for injection.

    Fig.6.SPC cube and abnormal batches distribution in the process space for generic aztreonam injections. (A) Abnormal batches distribution of 2012 NESTP, and (B) abnormal batches distribution of 2018 NESTP. The red cube is U, the blue cube is A1, the green cube is A0, and the colored markers are the batches out of A0.

    Fig.7.Annual comparison of process vector distribution of generic aztreonam injections. (A) 2012, and (B) 2018. (The colored vectors distributed in the space represent the comprehensive process control levels for each manufacturer.)

    CEAs are orthogonal in the interaction test, and the SPC parameter A0in the latest year was used as a reference(green cube in Fig.6).In Fig.6,the current ChP and latest SPC limitations were put into a 3D process space of CEAs. The abnormal batches distribution showed an obvious optimization of all CEAs. However,significant process problems were also observed,such as RC of M2 and M24, PS of M4, and both RC and PS of M5.

    The process risk assessments for the years 2012 and 2018 are illustrated in Fig. 7, where the PIs of risk for MC, PS and RC were used to construct a 3D quarter-spherical risk distribution space.We found that the risk distribution moved toward the lower risk direction from 2012 to 2018,which indicates an improvement in the overall process control trend. Although the overall process control trend is optimistic, the trend in individual processes varies. Some products, such as those from M2 and M17, showed an obvious increase in process control. M7 greatly improved the PS process but had a negative trend for RC. For M5, the risk for RC was slightly decreased, while that for both PS and MC increased. Thus, these manufacturers should focus on the relevant process problems and determine which factors lead to the risk increase in process control.Furthermore,it is worth noting that risk distribution assessment is useful for both process changes and process improvements with relative data supplementation for approval.

    4. Conclusions

    The advantages of the strategy we established for population pharmaceutical quality assessment are 1) a kind of processevaluation mechanism based on the QbD was established using structured drug quality data; 2) it offers a universal approach for assessing different industrial production processes for the same drug; 3) it can be applied to generic drugs consistency evaluation,process risk assessment and quality trend tracking, which can provide data-based information for approval.

    The established assessment strategy, which mines the process information related to population quality and investigates intrinsic links between QbD elements,provides a scientific tool for objectively and comprehensively evaluating quality consistency and promoting the regulation status of domestic generic drugs. Not only does this approach reflect the commonality in the different processes, but it also shows the development status of domestic pharmaceutical production processes over the past few years. From the regulatory perspective, it also reveals the gap between the quality target and the current process level. With continuous addition of information and data, dynamic trends of the population pharmaceutical quality could be observed for emergencies and for decision-making related to drug regulation based on the QbD concept.

    Declaration of competing interest

    The authors declare that there are no conflicts of interest.

    Acknowledgments

    The National Major Scientific and Technological Special Project for ‘Significant New Drugs Development’ (Grant No.:2017ZX0901001-007) provides support for this study.

    Appendix A. Supplementary data

    Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpha.2020.11.001.

    国产xxxxx性猛交| 母亲3免费完整高清在线观看 | 亚洲一区二区三区欧美精品| 色哟哟·www| 最后的刺客免费高清国语| 三级国产精品片| 午夜福利视频在线观看免费| 亚洲成色77777| 国产精品成人在线| 亚洲av电影在线观看一区二区三区| 曰老女人黄片| 精品人妻在线不人妻| 午夜福利在线观看免费完整高清在| 中文字幕人妻熟女乱码| 亚洲色图综合在线观看| 在线亚洲精品国产二区图片欧美| 九草在线视频观看| 一区在线观看完整版| 亚洲国产精品一区三区| 另类精品久久| 亚洲,欧美,日韩| 22中文网久久字幕| 国产亚洲欧美精品永久| 国内精品宾馆在线| 亚洲三级黄色毛片| 欧美精品一区二区大全| 精品久久国产蜜桃| 国产日韩欧美视频二区| 亚洲久久久国产精品| 亚洲激情五月婷婷啪啪| 久久午夜综合久久蜜桃| 婷婷色av中文字幕| 午夜视频国产福利| 一级爰片在线观看| 久久韩国三级中文字幕| 多毛熟女@视频| 男女国产视频网站| 国产亚洲午夜精品一区二区久久| √禁漫天堂资源中文www| 亚洲情色 制服丝袜| 高清不卡的av网站| 国产免费视频播放在线视频| 热99国产精品久久久久久7| 亚洲四区av| 97精品久久久久久久久久精品| 黄网站色视频无遮挡免费观看| 欧美 日韩 精品 国产| 亚洲av在线观看美女高潮| 亚洲欧美色中文字幕在线| 午夜视频国产福利| 亚洲经典国产精华液单| 永久免费av网站大全| 人人妻人人澡人人看| 欧美精品国产亚洲| 男人操女人黄网站| 另类亚洲欧美激情| 赤兔流量卡办理| 欧美+日韩+精品| 久久久国产精品麻豆| 国产成人精品久久久久久| 亚洲精品视频女| 99香蕉大伊视频| 日韩大片免费观看网站| 中国国产av一级| 亚洲色图综合在线观看| 免费日韩欧美在线观看| 青春草国产在线视频| 中文字幕亚洲精品专区| 亚洲精品久久成人aⅴ小说| 在线天堂中文资源库| 制服丝袜香蕉在线| 色吧在线观看| 男人爽女人下面视频在线观看| 一级毛片 在线播放| 亚洲色图综合在线观看| 97在线人人人人妻| 日本黄大片高清| 亚洲精品色激情综合| 欧美人与性动交α欧美软件 | 又大又黄又爽视频免费| 免费观看无遮挡的男女| 国产高清三级在线| 成人毛片a级毛片在线播放| 国产亚洲欧美精品永久| 三级国产精品片| 高清视频免费观看一区二区| 久久99热这里只频精品6学生| 色视频在线一区二区三区| 国产亚洲一区二区精品| 国产免费现黄频在线看| 国产一区亚洲一区在线观看| 老司机亚洲免费影院| 日韩精品免费视频一区二区三区 | 嫩草影院入口| 老女人水多毛片| 天堂中文最新版在线下载| 欧美精品国产亚洲| 国产无遮挡羞羞视频在线观看| 十八禁网站网址无遮挡| 我的女老师完整版在线观看| 女性被躁到高潮视频| 男人添女人高潮全过程视频| 日韩av不卡免费在线播放| 一级毛片电影观看| 黄色 视频免费看| 国产成人精品福利久久| 自拍欧美九色日韩亚洲蝌蚪91| 下体分泌物呈黄色| 久久久欧美国产精品| av在线观看视频网站免费| 人人澡人人妻人| 黄色 视频免费看| 久久精品人人爽人人爽视色| 欧美精品国产亚洲| 青春草国产在线视频| 亚洲精品美女久久久久99蜜臀 | 在线观看人妻少妇| 国产黄色免费在线视频| av卡一久久| 日本91视频免费播放| 最近最新中文字幕大全免费视频 | 亚洲在久久综合| 亚洲熟女精品中文字幕| 午夜福利影视在线免费观看| 天天影视国产精品| 91aial.com中文字幕在线观看| 久久青草综合色| 内地一区二区视频在线| 中文天堂在线官网| 久久人人爽av亚洲精品天堂| 日日啪夜夜爽| 伊人亚洲综合成人网| 久久ye,这里只有精品| 欧美丝袜亚洲另类| 国产免费现黄频在线看| 国产男人的电影天堂91| 国产成人欧美| 亚洲欧美一区二区三区黑人 | 国产精品99久久99久久久不卡 | 午夜福利乱码中文字幕| 国产极品粉嫩免费观看在线| 王馨瑶露胸无遮挡在线观看| 国产成人午夜福利电影在线观看| 国产成人91sexporn| 热99国产精品久久久久久7| 欧美变态另类bdsm刘玥| 日韩制服骚丝袜av| 久久久久国产精品人妻一区二区| 久久久久久久久久成人| 777米奇影视久久| 国产日韩欧美视频二区| 亚洲av电影在线进入| 国产欧美另类精品又又久久亚洲欧美| 激情视频va一区二区三区| 成人免费观看视频高清| 成人国产av品久久久| 国产精品欧美亚洲77777| 黄网站色视频无遮挡免费观看| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 汤姆久久久久久久影院中文字幕| 街头女战士在线观看网站| 夫妻午夜视频| 日韩欧美精品免费久久| 十八禁高潮呻吟视频| 免费女性裸体啪啪无遮挡网站| 成人国产av品久久久| 欧美日韩精品成人综合77777| 又粗又硬又长又爽又黄的视频| 美女xxoo啪啪120秒动态图| 一本大道久久a久久精品| 中文字幕制服av| 蜜桃在线观看..| 国产成人精品无人区| 菩萨蛮人人尽说江南好唐韦庄| 黄色怎么调成土黄色| 国产日韩欧美视频二区| 精品视频人人做人人爽| 欧美日韩综合久久久久久| 哪个播放器可以免费观看大片| 夫妻午夜视频| 五月天丁香电影| 亚洲国产看品久久| 欧美bdsm另类| 九色亚洲精品在线播放| 大陆偷拍与自拍| √禁漫天堂资源中文www| 欧美 日韩 精品 国产| 免费观看av网站的网址| 夫妻午夜视频| 极品少妇高潮喷水抽搐| av播播在线观看一区| 亚洲欧美清纯卡通| 欧美激情 高清一区二区三区| 亚洲欧美成人综合另类久久久| 国产老妇伦熟女老妇高清| 午夜福利,免费看| 精品一区二区三区四区五区乱码 | 最近中文字幕2019免费版| 国产男女内射视频| 乱人伦中国视频| 国产精品 国内视频| 亚洲色图综合在线观看| 欧美97在线视频| 日本av免费视频播放| 婷婷色综合www| 亚洲,欧美精品.| 极品人妻少妇av视频| 日韩 亚洲 欧美在线| 国产在线免费精品| 中文字幕最新亚洲高清| 极品少妇高潮喷水抽搐| 观看av在线不卡| 日本欧美国产在线视频| 十八禁网站网址无遮挡| 精品一区在线观看国产| 国产亚洲av片在线观看秒播厂| 2022亚洲国产成人精品| 国内精品宾馆在线| 波野结衣二区三区在线| 丰满迷人的少妇在线观看| 精品亚洲乱码少妇综合久久| 国产精品一国产av| 日韩 亚洲 欧美在线| 人人妻人人澡人人爽人人夜夜| 欧美少妇被猛烈插入视频| 亚洲图色成人| 黄片无遮挡物在线观看| 国产精品99久久99久久久不卡 | 久久av网站| av免费在线看不卡| 午夜精品国产一区二区电影| 91午夜精品亚洲一区二区三区| 亚洲婷婷狠狠爱综合网| 日本黄色日本黄色录像| 狂野欧美激情性xxxx在线观看| 极品少妇高潮喷水抽搐| 最黄视频免费看| a 毛片基地| 国产免费现黄频在线看| 久久久久久久精品精品| 亚洲美女搞黄在线观看| 久久久久久久久久人人人人人人| 欧美精品一区二区免费开放| 国产精品国产三级国产av玫瑰| av在线播放精品| 日韩一区二区三区影片| 中国美白少妇内射xxxbb| 男女啪啪激烈高潮av片| 夫妻午夜视频| 国产成人aa在线观看| 国产精品麻豆人妻色哟哟久久| 在线天堂最新版资源| 亚洲精品乱久久久久久| 亚洲av免费高清在线观看| 又黄又爽又刺激的免费视频.| 国产免费福利视频在线观看| 亚洲一级一片aⅴ在线观看| 午夜91福利影院| av黄色大香蕉| 成年美女黄网站色视频大全免费| 少妇的逼好多水| 黄网站色视频无遮挡免费观看| 欧美激情国产日韩精品一区| 丰满乱子伦码专区| 日本欧美视频一区| av免费在线看不卡| 亚洲av在线观看美女高潮| 黄片无遮挡物在线观看| 日韩一区二区三区影片| 日韩av不卡免费在线播放| 咕卡用的链子| 国产成人精品在线电影| 啦啦啦中文免费视频观看日本| 日韩精品免费视频一区二区三区 | 在线观看www视频免费| 纵有疾风起免费观看全集完整版| 婷婷色综合www| 亚洲中文av在线| 亚洲av电影在线观看一区二区三区| 国产日韩欧美在线精品| 极品人妻少妇av视频| 蜜桃国产av成人99| 日产精品乱码卡一卡2卡三| 国产精品久久久久成人av| 女人久久www免费人成看片| 中文字幕最新亚洲高清| 赤兔流量卡办理| 亚洲国产欧美在线一区| 欧美精品高潮呻吟av久久| 视频区图区小说| 天堂俺去俺来也www色官网| 大话2 男鬼变身卡| 大香蕉97超碰在线| 国产精品久久久久久久电影| 91精品国产国语对白视频| 亚洲,欧美精品.| 午夜久久久在线观看| 丁香六月天网| 99热网站在线观看| 97在线人人人人妻| 搡女人真爽免费视频火全软件| 韩国高清视频一区二区三区| 18在线观看网站| 老司机影院成人| 精品国产一区二区三区久久久樱花| 亚洲精品av麻豆狂野| 午夜福利,免费看| 免费av中文字幕在线| 在线观看人妻少妇| av免费在线看不卡| 日本91视频免费播放| 亚洲美女视频黄频| 天天躁夜夜躁狠狠躁躁| 69精品国产乱码久久久| 如何舔出高潮| av福利片在线| 久久久久久久大尺度免费视频| 久久99精品国语久久久| 99热全是精品| av在线观看视频网站免费| 水蜜桃什么品种好| 男的添女的下面高潮视频| 欧美人与性动交α欧美软件 | 国产精品一区www在线观看| 免费观看在线日韩| 国产在视频线精品| 九九在线视频观看精品| 国语对白做爰xxxⅹ性视频网站| 女性生殖器流出的白浆| 国产精品久久久久久av不卡| 精品少妇黑人巨大在线播放| 久久影院123| 国产午夜精品一二区理论片| 亚洲精品国产色婷婷电影| 久久精品熟女亚洲av麻豆精品| 国产欧美另类精品又又久久亚洲欧美| 国产亚洲av片在线观看秒播厂| 亚洲国产av影院在线观看| 亚洲精品国产av蜜桃| 香蕉国产在线看| 亚洲五月色婷婷综合| av网站免费在线观看视频| 老司机影院成人| 日本-黄色视频高清免费观看| 一级毛片我不卡| videosex国产| 男男h啪啪无遮挡| 成年人免费黄色播放视频| 国产综合精华液| 国产不卡av网站在线观看| 欧美少妇被猛烈插入视频| 久久精品aⅴ一区二区三区四区 | 91在线精品国自产拍蜜月| 18禁国产床啪视频网站| 亚洲欧洲精品一区二区精品久久久 | 日日撸夜夜添| 丝袜喷水一区| 亚洲综合色网址| 国产精品久久久av美女十八| 大片电影免费在线观看免费| 免费人成在线观看视频色| 啦啦啦在线观看免费高清www| 午夜影院在线不卡| 2018国产大陆天天弄谢| 少妇被粗大的猛进出69影院 | 午夜福利视频在线观看免费| 五月玫瑰六月丁香| 秋霞伦理黄片| 91久久精品国产一区二区三区| 精品一品国产午夜福利视频| 夫妻午夜视频| 午夜免费男女啪啪视频观看| 亚洲情色 制服丝袜| 亚洲国产精品999| 亚洲精品国产色婷婷电影| 国产午夜精品一二区理论片| 国产日韩一区二区三区精品不卡| 亚洲精品美女久久久久99蜜臀 | 大陆偷拍与自拍| 午夜91福利影院| 波野结衣二区三区在线| 亚洲精品国产av成人精品| 国产有黄有色有爽视频| 中文乱码字字幕精品一区二区三区| 最近最新中文字幕大全免费视频 | 一区二区三区精品91| 韩国高清视频一区二区三区| 五月伊人婷婷丁香| 乱人伦中国视频| 日日撸夜夜添| 欧美97在线视频| 国产激情久久老熟女| 免费人成在线观看视频色| 日本猛色少妇xxxxx猛交久久| 精品一品国产午夜福利视频| av天堂久久9| 亚洲国产精品999| 综合色丁香网| 性高湖久久久久久久久免费观看| 久久精品国产综合久久久 | 水蜜桃什么品种好| 在线观看免费日韩欧美大片| 香蕉精品网在线| 26uuu在线亚洲综合色| 久久久久久人人人人人| www.色视频.com| 国产亚洲av片在线观看秒播厂| 亚洲成国产人片在线观看| 久久国产精品男人的天堂亚洲 | 久久久久精品人妻al黑| 亚洲高清免费不卡视频| 国产成人精品久久久久久| av女优亚洲男人天堂| 亚洲激情五月婷婷啪啪| 欧美3d第一页| 人人妻人人澡人人看| 十八禁高潮呻吟视频| 亚洲精品乱久久久久久| 精品人妻在线不人妻| 一级a做视频免费观看| 久久久欧美国产精品| 久久热在线av| 在线天堂中文资源库| 人人妻人人添人人爽欧美一区卜| 国产不卡av网站在线观看| 免费久久久久久久精品成人欧美视频 | 中文乱码字字幕精品一区二区三区| 亚洲成色77777| 久久影院123| 男女午夜视频在线观看 | 97精品久久久久久久久久精品| 亚洲国产日韩一区二区| 男女国产视频网站| 亚洲欧美色中文字幕在线| 69精品国产乱码久久久| 少妇熟女欧美另类| 亚洲欧美一区二区三区黑人 | 人妻少妇偷人精品九色| 精品国产一区二区三区久久久樱花| 精品少妇久久久久久888优播| 国产精品人妻久久久久久| 欧美精品国产亚洲| 日日啪夜夜爽| 日韩伦理黄色片| 黄网站色视频无遮挡免费观看| 永久免费av网站大全| 国语对白做爰xxxⅹ性视频网站| 国产在线免费精品| 天堂8中文在线网| 另类亚洲欧美激情| 有码 亚洲区| 夜夜爽夜夜爽视频| 亚洲精品乱久久久久久| 国产乱人偷精品视频| 最黄视频免费看| 高清在线视频一区二区三区| 亚洲综合色网址| 亚洲欧美成人精品一区二区| 黄色毛片三级朝国网站| 全区人妻精品视频| 97人妻天天添夜夜摸| 国产精品成人在线| a 毛片基地| 婷婷色麻豆天堂久久| 久久精品夜色国产| 26uuu在线亚洲综合色| 在线观看人妻少妇| 91久久精品国产一区二区三区| 精品人妻熟女毛片av久久网站| 精品卡一卡二卡四卡免费| 国产成人精品久久久久久| 亚洲五月色婷婷综合| 五月伊人婷婷丁香| 亚洲欧美色中文字幕在线| av一本久久久久| 亚洲在久久综合| 午夜91福利影院| 精品福利永久在线观看| 国产成人欧美| 极品人妻少妇av视频| 精品视频人人做人人爽| 久久久久久久精品精品| av.在线天堂| 久久久久国产精品人妻一区二区| 日韩伦理黄色片| 在线观看一区二区三区激情| 青春草亚洲视频在线观看| 国产一区二区激情短视频 | 日日啪夜夜爽| 黑人猛操日本美女一级片| 免费看光身美女| 亚洲精品国产av成人精品| 男女啪啪激烈高潮av片| 中文字幕免费在线视频6| 在线观看三级黄色| 伦精品一区二区三区| 咕卡用的链子| 亚洲av国产av综合av卡| 精品99又大又爽又粗少妇毛片| 国产精品人妻久久久影院| 熟女av电影| 热re99久久国产66热| 天天操日日干夜夜撸| 国产无遮挡羞羞视频在线观看| 亚洲综合色惰| 国产不卡av网站在线观看| 毛片一级片免费看久久久久| 久久久久久久久久久久大奶| 纯流量卡能插随身wifi吗| 国产男人的电影天堂91| 国产探花极品一区二区| 亚洲av免费高清在线观看| 日本与韩国留学比较| 乱人伦中国视频| 国国产精品蜜臀av免费| 成年人免费黄色播放视频| 亚洲四区av| 日本av免费视频播放| 丝袜喷水一区| 亚洲情色 制服丝袜| 99国产综合亚洲精品| 亚洲五月色婷婷综合| 久久这里只有精品19| 精品人妻在线不人妻| 国产1区2区3区精品| 久久99一区二区三区| 啦啦啦啦在线视频资源| 最近最新中文字幕免费大全7| 亚洲欧美成人精品一区二区| 国产免费视频播放在线视频| 伊人亚洲综合成人网| 久久久久久久国产电影| 精品久久国产蜜桃| 成年人免费黄色播放视频| 国产精品嫩草影院av在线观看| av播播在线观看一区| 一个人免费看片子| 亚洲精品久久久久久婷婷小说| 国产亚洲一区二区精品| 最近最新中文字幕免费大全7| 欧美激情 高清一区二区三区| 午夜老司机福利剧场| 亚洲精品久久久久久婷婷小说| 日日啪夜夜爽| 欧美另类一区| www.av在线官网国产| 国产片特级美女逼逼视频| 美女主播在线视频| 成年动漫av网址| 一区二区三区四区激情视频| 交换朋友夫妻互换小说| 内地一区二区视频在线| 精品一区在线观看国产| 色网站视频免费| 99热这里只有是精品在线观看| 一级毛片 在线播放| 深夜精品福利| 女性被躁到高潮视频| av福利片在线| 美女中出高潮动态图| 久久国产亚洲av麻豆专区| 日韩人妻精品一区2区三区| 18禁观看日本| 激情五月婷婷亚洲| 精品国产露脸久久av麻豆| 一级黄片播放器| 成人国产av品久久久| 一二三四在线观看免费中文在 | 久久精品久久久久久久性| 我的女老师完整版在线观看| 欧美+日韩+精品| 中文乱码字字幕精品一区二区三区| 少妇被粗大猛烈的视频| 人妻 亚洲 视频| 精品国产国语对白av| 男女边摸边吃奶| 亚洲精品一区蜜桃| 国产精品女同一区二区软件| 男女免费视频国产| 天天躁夜夜躁狠狠躁躁| 国产视频首页在线观看| av.在线天堂| 女人被躁到高潮嗷嗷叫费观| 欧美国产精品一级二级三级| 99精国产麻豆久久婷婷| 婷婷色av中文字幕| 国产精品三级大全| 大陆偷拍与自拍| 成人二区视频| 亚洲欧洲日产国产| 色网站视频免费| 婷婷成人精品国产| 亚洲国产av影院在线观看| 国产日韩欧美在线精品| 哪个播放器可以免费观看大片| 在线观看免费高清a一片| 国产精品不卡视频一区二区| 狂野欧美激情性xxxx在线观看| 十八禁网站网址无遮挡| 99久久综合免费| 欧美最新免费一区二区三区| 日韩 亚洲 欧美在线| 26uuu在线亚洲综合色| 国产精品久久久av美女十八| 久久久久久久久久久久大奶| 晚上一个人看的免费电影| 日韩中文字幕视频在线看片| 中国美白少妇内射xxxbb| 精品久久久精品久久久| 欧美亚洲 丝袜 人妻 在线| 黑人巨大精品欧美一区二区蜜桃 | 精品卡一卡二卡四卡免费| 一级毛片黄色毛片免费观看视频| 国产乱来视频区| 久久免费观看电影|